Oxford Biomedica PLC

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

Supposedly Defensive Investments The biotech sector goes through boom and bust. I describe the period in the aftermath of a biotech bubble as a ‘wilderness period’, during which stock prices stagnate,

Rising Leaders Home Lara Mott, CEO and co-founder of ImproveWell, likens her company’s real-time feedback tool for frontline staff to a smoke detector for health care. The software platform, called t

Drug access and supply-chain issues have remained challenging in the aftermath of the COVID-19 pandemic, while increasing research and development in the cell and gene therapy fields are expected to y